Authors
Funda Meric-Bernstam, Seung Tae Kim, Napa Parinyanitikul, Alberto Moreno, Chia-Chi Lin, Dmitry Gornastolev, Jarin Chindaprasirt, Iwona A Lugowska, Daniil Stroyakovskiy, Jacek Jassem, Michelle L Harrison, Vikas S Ostwal, Flavia Michelini, Lindsey Jung, Nataliya Kuptsova-Clarkson, Soham D Puvvada, Hui Kong Gan
Publication date
2024/6/1
Source
Journal of Clinical Oncology
Volume
42
Issue
16_suppl
Pages
6037-6037
Publisher
American Society of Clinical Oncology
Description
6037
Background: In DP-02, T-DXd demonstrated an objective response rate (ORR) by investigator (INV) of 37.1% (95% CI 31.3, 43.2) and clinically meaningful survival outcomes in 267 pretreated pts with HER2-expressing tumors. In this post-hoc analysis, we report outcomes and characterize those with an objective response (OR) in a subset of pts with head and neck cancers (previously included in the ‘other tumor’ cohort), most of which were salivary gland tumors. Methods: This open-label, Phase 2 study (NCT04482309) evaluated T-DXd (5.4 mg/kg Q3W) in pts with HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced/metastatic disease after ≥1 systemic treatment or without treatment options. The primary endpoint was confirmed ORR by INV. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), disease control rate (DCR …
Scholar articles
F Meric-Bernstam, ST Kim, N Parinyanitikul, A Moreno… - 2024